Many different drug categories are used in pharmacological research on the ERK pathway (Table 1), such as traditional Chinese medicine (TCM) and natural drug components, which can delay the progression of ischemic diseases by interfering with angiogenesis. The gene discussed is MAPK1; the disease is ischemic disease.